A clinical study to compare high flow nasal oxygen and non invasive ventilation in patients with covid-19.
Phase 2
Completed
- Conditions
- Health Condition 1: J09X- Influenza due to identified novelinfluenza A virusHealth Condition 2: J09X- Influenza due to identified novelinfluenza A virusHealth Condition 3: J22- Unspecified acute lower respiratory infection
- Registration Number
- CTRI/2020/11/029356
- Lead Sponsor
- BLDED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 82
Inclusion Criteria
Patients with COVID-19 rtPCR positive who requires HFNO and NIV as first line therapy.
Patients aged between 20-60years and weighing 40-80kg.
Exclusion Criteria
Patients with
pH < 7.20
Children
Comorbidities like renal, cardiac and liver failure and morbid obesity.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in respiratory distress signs like decrease in respiratory rate and increase in saturation SpO2 90%. <br/ ><br> Improvement in hemodynamic stability such as Heart rate, respiratory rate and blood pressure. <br/ ><br>Timepoint: ON ADMISSION <br/ ><br>6 HOURS <br/ ><br>12 HOURS <br/ ><br>24 HOURS <br/ ><br>2ND DAY <br/ ><br>4TH to 6TH DAY <br/ ><br>1ST WEEK
- Secondary Outcome Measures
Name Time Method Improvement in chest x-ray/High Resolution Computerised Tomography. <br/ ><br>ICU stay and outcome of HFNO and NIV. <br/ ><br>Incidence of failed HFNO and NIV who needs intubation.Timepoint: ON ADMISSION <br/ ><br>6 HOURS <br/ ><br>12 HOURS <br/ ><br>24 HOURS <br/ ><br>2ND DAY <br/ ><br>4TH to 6TH DAY <br/ ><br>1ST WEEK